THNR Holdings — Amplify Weight Loss Drug & Treatment ETF
All 21 reported holdings of Amplify Weight Loss Drug & Treatment ETF (THNR) by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets | Value (USD) |
|---|---|---|
| Novo Nordisk A/S | 11.89% | $493.59K |
| Eli Lilly & Co | 11.56% | $480.12K |
| Regeneron Pharmaceuticals Inc | 6.77% | $281.24K |
| Amgen Inc | 6.27% | $260.37K |
| Chugai Pharmaceutical Co Ltd | 6.00% | $248.98K |
| CSPC Pharmaceutical Group Ltd | 5.03% | $208.92K |
| Arrowhead Pharmaceuticals Inc | 4.96% | $206.09K |
| AbbVie Inc | 4.75% | $197.26K |
| AstraZeneca PLC | 4.66% | $193.28K |
| Pfizer Inc | 4.62% | $191.73K |
| Merck & Co Inc | 4.48% | $185.97K |
| Shionogi & Co Ltd | 4.46% | $185.34K |
| Roche Holding AG | 4.46% | $185.24K |
| Innovent Biologics Inc | 4.43% | $184.09K |
| Invesco Government & Agency Po | 2.97% | $123.11K |
| Scholar Rock Holding Corp | 2.37% | $98.57K |
| Viking Therapeutics Inc | 2.21% | $91.70K |
| Structure Therapeutics Inc | 2.02% | $83.77K |
| Zealand Pharma A/S | 1.74% | $72.05K |
| Hanmi Pharm Co Ltd | 1.28% | $53.13K |
| Jiangsu Hengrui Pharmaceutical | 1.23% | $51.01K |
THNR overview: performance, fees, allocation and SEC filings